Interfax has announced that Sputnik V is currently approved for emergency use in 31 countries around the world.
Syria has registered the Russian vaccine Sputnik V and authorized its use on its territory. This was announced on Monday in Moscow by the Syrian ambassador to Russia Riyadh Haddad.
Last December, Syria also joined the global COVAX initiative, which aims to accelerate the development and production of tests, treatments and vaccines against COVID-19 and ensure equitable access to them.
AFP recalled that the World Health Organization (WHO), together with the United Nations Children’s Fund (UNICEF) and the Global Alliance for Vaccines and Vaccines (GAVI), have declared their intention to support Syria in obtaining vaccines so that at least three percent of the Syrian population will initially receive it. The goal is to vaccinate another 20 percent of Syria’s population by the end of this year, AFP added.
There were 15,179 SARS-CoV-2 coronavirus infections and 998 related deaths in government-controlled areas of Syria. Kurdish territories in the north-east of the country record 8600 cases and 311 deaths, while in northwestern Syria – controlled by anti-government insurgents – there are 21,121 infected and 408 deaths.
Interfax has announced that Sputnik V is currently approved for emergency use in 31 countries, including Russia, Mexico, Argentina, Bolivia, Iran and the only EU country, Hungary.
In Europe, according to Interfax, it is also vaccinated in Serbia and the Serbian entity in Bosnia and Herzegovina.
Negotiations on the supply of Sputnik V have also begun in Croatia with Russia.
Sputnik V in Russia was approved in August last year as the first ever vaccine against COVID-19. However, the approval took place before the third phase of the clinical trial, which aroused distrust and caution in part of the scientific and medical community.
They started vaccinating the general population with Sputnik V after testing the vaccine in only the third phase of the trials. Usually, the vaccine is tested in the third phase on thousands of volunteers and much longer.
After this third round of clinical trials, the results of a study published in the scientific journal Lancet were published in early February 2021. According to published data, the Russian vaccine achieves a success rate of 91.6 percent, which is similar in effectiveness to the Pfizer / BioNTech or Moderna vaccines.
#Coronavirus #Syria #registered #Russian #vaccine #Sputnik #authorized